In a 45-year-old woman with irregular menstrual cycles, what tests should be performed for evaluation?

Evaluation of Irregular Menstrual Cycles at Age 45

In a 45-year-old woman with irregular menstrual cycles, begin with pregnancy testing, followed by TSH, prolactin, and FSH levels to distinguish between perimenopausal transition and pathologic causes requiring intervention.

Initial Essential Testing

At age 45, irregular cycles most commonly represent the perimenopausal transition, but you must exclude treatable pathology before attributing symptoms to normal aging. The evaluation should proceed systematically:

First-Line Laboratory Tests

All women require:

• Pregnancy test (β-hCG) - Pregnancy remains possible and must be excluded first 1, 2, 3
• TSH - Thyroid dysfunction commonly presents with menstrual irregularity 1, 2, 4
• Prolactin - Hyperprolactinemia can cause amenorrhea or irregular bleeding; obtain morning resting levels 5, 2, 4
• FSH - Elevated FSH (>35 IU/L) indicates ovarian failure/premature ovarian insufficiency, while normal/low FSH suggests other etiologies 5, 6

The timing matters: Draw FSH between cycle days 3-6 if cycles are still occurring 5. An elevated FSH confirms perimenopausal transition or premature ovarian insufficiency, while normal FSH with irregular cycles suggests ovulatory dysfunction requiring further evaluation.

Additional Testing Based on Clinical Features

If hyperandrogenic signs present (hirsutism, acne, male-pattern hair loss):

• Total testosterone - Early morning, days 3-6 of cycle if possible 5, 7, 5
• DHEA-S - To exclude adrenal source 5
• 17-hydroxyprogesterone - If high-risk ethnicity or family history suggests congenital adrenal hyperplasia 7, 4

If anovulation suspected (cycles >35 days apart):

• Mid-luteal progesterone - Levels <6 nmol/L indicate anovulation 5
• Fasting glucose and insulin - PCOS commonly presents with metabolic dysfunction 5

Structural Evaluation

Endometrial assessment is critical at this age:

• Women ≥35 years with irregular bleeding require endometrial biopsy to exclude hyperplasia or malignancy, especially with risk factors (obesity, anovulation, diabetes) 8, 9
• Transvaginal ultrasound evaluates for structural lesions (fibroids, polyps) and can assess endometrial thickness 1, 5

The combination of irregular cycles and unopposed estrogen from anovulation increases endometrial cancer risk, making tissue diagnosis essential in this age group 8.

Algorithmic Approach

Step 1: Pregnancy test

• If positive → obstetric care
• If negative → proceed

Step 2: TSH, prolactin, FSH

• FSH >35 IU/L → Premature ovarian insufficiency; consider karyotype, FMR1 premutation, anti-TPO antibodies, bone density 6
• Elevated prolactin → Brain MRI to exclude pituitary adenoma 2, 4
• Abnormal TSH → Treat thyroid disorder
• All normal → proceed to Step 3

Step 3: Assess for hyperandrogenism and anovulation

• Clinical hyperandrogenism or irregular cycles >35 days → Add testosterone, DHEA-S, mid-luteal progesterone, fasting glucose/insulin 5
• Evidence of PCOS → Pelvic ultrasound for ovarian morphology 5, 4

Step 4: Endometrial protection

• Any woman ≥35 with irregular bleeding → Endometrial biopsy 8, 9
• Consider transvaginal ultrasound if structural lesions suspected 1

Critical Pitfalls to Avoid

Don't assume perimenopause without testing. While age 45 makes perimenopausal transition likely, premature ovarian insufficiency, thyroid disease, and PCOS all present with irregular cycles and require different management strategies affecting long-term morbidity 6, 9.

Don't skip endometrial assessment. Chronic anovulation at any age creates unopposed estrogen exposure, but the cancer risk escalates significantly after age 35. Irregular bleeding in this age group mandates tissue diagnosis 8, 9.

Don't obtain FSH during active bleeding or random cycle timing. FSH fluctuates throughout the cycle; only early follicular phase values (days 3-6) are interpretable 5. In amenorrhea, timing is less critical.

Don't order comprehensive hormone panels indiscriminately. The evidence supports targeted testing based on clinical presentation rather than reflexive "menopause panels" 7, 2, 4. LH/FSH ratios and estradiol levels add limited value beyond FSH alone for distinguishing perimenopause from other causes.

Special Considerations

If the patient has epilepsy or takes valproic acid, the threshold for investigating PCOS should be lower, as these conditions increase PCOS prevalence to 10-25% 5.

Women with confirmed premature ovarian insufficiency (FSH >35 IU/L before age 40) require bone density screening, cardiovascular risk assessment, and hormone replacement until age 51 6.